title: Pattern of bacterial diseases in a cohort of HIV-1 infected adults receiving cotrimoxazole prophylaxis in Abidjan, Côte d'Ivoire.
abstract: BACKGROUND
  WHO/UNAIDS recommended that cotrimoxazole should be prescribed in Africa in HIV-infected adults with CD4 cell counts < 500 x 10 /l, while closely monitoring bacterial diseases in as many settings as possible.
  
  
  METHODS
  Prospective cohort study, describing bacterial morbidity in adults receiving cotrimoxazole prophylaxis (960 mg daily) between April 1996 and June 2000 in Abidjan, Côte d'Ivoire.
  
  
  RESULTS
  Four-hundred and forty-eight adults (median baseline CD4 cell count 251 x 10 /l) were followed for a median time of 26 months. The rates of overall bacterial diseases and of serious bacterial diseases with hospital admission were 36.8/100 person-years (PY) and 11.3/100 PY, respectively. Bacterial diseases were the first causes of hospital admissions, followed by non-specific enteritis (10.2/100 PY), acute unexplained fever (8.4/100 PY), and tuberculosis (3.6/100 PY). Among serious bacterial diseases, the most frequent were enteritis (3.0/100 PY), invasive urogenital infections (2.5/100 PY), pneumonia (2.3/100 PY), bacteraemia with no focus (2.0/100 PY), upper respiratory tract infections (1.6/100 PY) and cutaneous infections (0.6/100 PY). Compared with patients with baseline CD4+ cell counts >or= 200 x 10 /l, other patients had an adjusted hazard ratio of serious bacterial diseases of 3.05 (95% confidence interval, 2.00-4.67; < 0.001). Seventy-five bacterial strains were isolated during serious episodes including 29 non-, 14, 12 spp, and 12.
  
  
  CONCLUSIONS
  Though with a medium-term rate half that of the short-term rate estimated under placebo before 1998 (26.1/100 PY), serious bacterial morbidity remains the first cause of hospital admission in adults receiving cotrimoxazole in this setting.
authors.affiliation: INSERM U330, Université Victor Segalen, Bordeaux, France.
authors.forename: Xavier
authors.initials: X
authors.lastname: Anglaret
authors.forename: Eugène
authors.initials: E
authors.lastname: Messou
authors.forename: Timothée
authors.initials: T
authors.lastname: Ouassa
authors.forename: Siaka
authors.initials: S
authors.lastname: Toure
authors.forename: Nicole
authors.initials: N
authors.lastname: Dakoury-Dogbo
authors.forename: Patrice
authors.initials: P
authors.lastname: Combe
authors.forename: Allassane
authors.initials: A
authors.lastname: Mahassadi
authors.forename: Catherine
authors.initials: C
authors.lastname: Seyler
authors.forename: Thérèse
authors.initials: T
authors.lastname: N'Dri-Yoman
authors.forename: Roger
authors.initials: R
authors.lastname: Salamon
mesh_terms: D000328:Adult; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000150:complications*; D018791:CD4 Lymphocyte Count; D007560:Cote d'Ivoire; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000276:immunology / Q000382:microbiology* / Q000517:prevention & control*; D015497:HIV-1; D006801:Humans; D015994:Incidence; D008297:Male; D009017:Morbidity; D011446:Prospective Studies; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use*
chemical_list: D000890:Anti-Infective Agents; D015662:Trimethoprim, Sulfamethoxazole Drug Combination